ro-09-0410 and Common-Cold

Topics: Animals; Antiviral Agents; Chalcone; Chalcones; Clinical Trials as Topic; Common Cold; Drug Resistance, Microbial; Flavonoids; Hepatitis B; Humans; Mice; Picornaviridae; Rhinovirus; RNA, Viral; Simplexvirus; Structure-Activity Relationship; Viral Vaccines

Topics: Benzimidazoles; Chalcone; Chalcones; Common Cold; Flavonoids; Humans; Interferon Type I; Oximes; Rhinovirus; Sulfonamides

The antirhinovirus agent chalcone Ro 09-0410 was tested in double-blind place-controlled volunteer trials for its protective efficacy against experimental rhinovirus infection. Fifty volunteers received either drug (26 volunteers) or placebo (24 volunteers) both before and after challenge with 20-40 tissue culture infecting dose (TCID50) of human rhinovirus 2 (RV2). There was no evidence that medication significantly reduced the incidence of infection or illness, indeed there was some increase in the nasal secretion produced.

Topics: Administration, Intranasal; Antiviral Agents; Chalcone; Chalcones; Clinical Trials as Topic; Common Cold; Double-Blind Method; Female; Humans; Male; Propiophenones

Topics: Animals; Antiviral Agents; Chalcone; Chalcones; Clinical Trials as Topic; Common Cold; Drug Resistance, Microbial; Flavonoids; Hepatitis B; Humans; Mice; Picornaviridae; Rhinovirus; RNA, Viral; Simplexvirus; Structure-Activity Relationship; Viral Vaccines

Ro 09-0415, a phosphorylated 'pro-drug' of the potent antirhinovirus compound, 4' ethoxy-2'-hydroxy-4, 6' dimethoxy-chalcone (Ro 09-0410) was tested in a double-blind placebo-controlled trial for its protective effect against experimental rhinovirus infection. The maximum dose, 1200 mg bd, based on considerations of practicality and tolerance was given orally both before and after challenge with a sensitive rhinovirus, type 9. Plasma concentrations of active compound in excess of those required for the inhibition of rhinovirus type 9 in vitro were achieved, but there was no evidence to suggest that treatment with Ro 09-0415 had a beneficial effect. It is concluded that Ro 09-0415 given orally is unlikely to be of value in the prophylaxis or therapy of human rhinovirus infection.

Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Chalcone; Chalcones; Clinical Trials as Topic; Common Cold; Double-Blind Method; Female; Humans; Male; Middle Aged; Propiophenones; Rhinovirus